Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

248
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
248
Tumor Immunotherapy01:27

Tumor Immunotherapy

636
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
636
T Cell Types and Functions01:24

T Cell Types and Functions

1.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.3K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.1K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.1K
Inflammatory Response01:28

Inflammatory Response

4.8K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
4.8K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory Bowel Disease Is Associated With an Increased Risk of End-Stage Renal Disease: A Population-Based Cohort Study.

Alimentary pharmacology & therapeutics·2026
Same author

All-cause and cause-specific mortality in inflammatory bowel disease across the biologic era: a population-based matched cohort study.

Journal of Crohn's & colitis·2026
Same author

Impact of depression and anxiety on health-related quality of life changes over time within individuals with rheumatoid arthritis or inflammatory bowel disease: A prospective Canadian cohort study.

PloS one·2026
Same author

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

medRxiv : the preprint server for health sciences·2026
Same author

Inflammatory bowel disease phenotypes in diverse populations: a global comparative analysis.

Journal of Crohn's & colitis·2026
Same author

Enumeration, Phenotyping, and Clinical Associations of Tissue-Resident T Cells in the Ecto- and Endocervix of Women Attending a Colposcopy Clinic.

American journal of reproductive immunology (New York, N.Y. : 1989)·2026

Related Experiment Video

Updated: Aug 21, 2025

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

397

Immunomodulators: still having a role?

Jeffery M Venner1,2, Charles N Bernstein1,2

  • 1University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada.

Gastroenterology Report
|November 16, 2022
PubMed
Summary

Thiopurines and methotrexate remain crucial for inflammatory bowel disease management, especially for maintaining remission and in combination therapy. These immunomodulators offer continued benefits despite newer treatments.

Keywords:
6-mercaptopurine (6-MP)Crohn’s diseaseazathioprineimmunomodulatorsmethotrexate

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.5K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.4K

Related Experiment Videos

Last Updated: Aug 21, 2025

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

397
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.5K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.4K

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Immunomodulators like thiopurines and methotrexate have been mainstays in inflammatory bowel disease (IBD) treatment for over four decades.
  • Despite the emergence of biologics and small molecules, these traditional agents retain significant clinical relevance.

Purpose of the Study:

  • To review the established role and ongoing utility of immunomodulators in Crohn's disease management.
  • To highlight their benefits in specific therapeutic contexts, such as remission maintenance and combination therapy.

Main Methods:

  • Literature review of clinical studies and therapeutic guidelines.
  • Analysis of data concerning the efficacy and safety of thiopurines and methotrexate in Crohn's disease.

Main Results:

  • Thiopurines and methotrexate continue to be valuable for long-term Crohn's disease remission.
  • Combination therapy with infliximab may mitigate anti-drug antibody formation.

Conclusions:

  • Immunomodulators, including thiopurines and methotrexate, offer sustained benefits in Crohn's disease therapy.
  • Their use is supported by extensive data, particularly for maintenance and combination strategies, despite acknowledged limitations.